Abstract
Abstract
Aim
The study aims to increase understanding of edaravone’s efficacy and safety as an amyotrophic lateral sclerosis (ALS) treatment and provide significant insights regarding this field’s future research.
Methods
We conducted a comprehensive search of the Embase, PubMed, Cochrane Library, Web of Science, and Scopus databases for randomized controlled trials and observational studies up until September 2022. We evaluated the studies’ quality using the Cochrane risk of bias tool and the National Institutes of Health tool.
Results
We included 11 studies with 2845 ALS patients. We found that edaravone improved the survival rate at 18, 24, and 30 months (risk ratio (RR) = 1.03, 95% confidence interval (CI) [1.02 to 1.24], P = 0.02), (RR = 1.22, 95% CI [1.06 to 1.41], P = 0.007), and (RR = 1.17, 95% CI [1.01 to 1.34], P = 0.03), respectively. However, the administration of edaravone did not result in any significant difference in adverse effects or efficacy outcomes between the two groups, as indicated by a P value greater than 0.05.
Conclusion
Edaravone improves survival rates of ALS patients at 18, 24, and 30 months with no adverse effects. However, edaravone does not affect functional outcomes. In order to ensure the validity of our findings and assess the results in accordance with the disease stage, it is essential to carry out additional prospective, rigorous, and high-quality clinical trials. The current study offers preliminary indications regarding the effectiveness and safety of edaravone. However, further comprehensive research is required to establish the generalizability and sustainability of the findings.
Publisher
Springer Science and Business Media LLC
Subject
Psychiatry and Mental health,Neurology (clinical),Dermatology,General Medicine
Reference36 articles.
1. Brotman RG, Moreno-Escobar MC, Joseph J et al (2022) Amyotrophic lateral sclerosis. In: StatPearls. Treasure Island (FL): StatPearls Publishing. Available from: https://www.ncbi.nlm.nih.gov/books/NBK556151/
2. Raymond J, Oskarsson B, Mehta P, Horton K (2019) Clinical characteristics of a large cohort of US participants enrolled in the National Amyotrophic Lateral Sclerosis (ALS) Registry, 2010–2015. Amyotroph Lateral Scler Frontotemporal Degener 20(5–6):413–420
3. Xu L, Liu T, Liu L, Yao X, Chen L, Fan D et al (2020) Global variation in prevalence and incidence of amyotrophic lateral sclerosis: a systematic review and meta-analysis. J Neurol 267(4):944–953
4. Mehta P, Raymond J, Punjani R, Han M, Larson T, Kaye W et al (2017) Prevalence of amyotrophic lateral sclerosis in the United States using established and novel methodologies. Amyotroph Lateral Scler Frontotemporal Degener 2022:1–9
5. Wijesekera LC, Nigel LP (2009) Amyotrophic lateral sclerosis. Orphanet J Rare Dis 4(1):3
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献